Ipamorelin is a synthetic pentapeptide that tells the pituitary to release a pulse of growth hormone. Researchers reach for it when they want that signal clean, without the extra hormonal noise older secretagogues carry. This dossier is a reference for research use. It is not medical advice and not a how-to for self-administration.
What Ipamorelin is
The molecule is a chain of five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2). It belongs to the growth hormone secretagogue family, the same broad group as GHRP-6 and GHRP-2. A Novo Nordisk research group first described it in the late 1990s, and the early papers are why it still gets cited. They showed a secretagogue that released growth hormone with far fewer off-target effects than what came before.
How it works
Ipamorelin binds the ghrelin receptor, GHS-R1a, in the pituitary and hypothalamus. That is the same receptor the body's own ghrelin uses. Two things follow. The pituitary releases stored growth hormone, and somatostatin, the brake that normally shuts a GH pulse down, is partly held back. In study models the result is a short, defined pulse rather than a flat, constant elevation. The half-life sits near two hours, so the effect is pulsatile by nature.
The selectivity that made it interesting
What separated Ipamorelin from the earlier peptides was what it did not do. In the foundational comparisons it raised growth hormone without a meaningful rise in cortisol, ACTH or prolactin, and without the sharp hunger spike GHRP-6 is known for. For a research setting that matters, because it lets a study attribute an effect to the GH axis rather than to a stress-hormone or appetite confound. If you want the deeper mechanism write-up, the GHRP-6 monograph lays out the contrast side by side.
Ipamorelin and GHRP-6
The two are often studied together because they answer different questions. GHRP-6 is the stronger appetite stimulant and pushes a larger GH release, but it drags cortisol and prolactin along with it. Ipamorelin trades some of that raw output for a cleaner profile. The GHRP-6 vs CJC-1295 DAC comparison walks through where each one fits.
The CJC-1295 and Ipamorelin pairing
This is the combination the peptide literature returns to most. The logic is simple. A GHRH analog like CJC-1295 acts on the GHRH receptor and sets how large a GH pulse can be. Ipamorelin acts on a different receptor, the GHS-R, and it both triggers the release and lifts the somatostatin brake. Because the two work through separate doors, their effect on GH release adds up rather than overlapping. That is why so many research protocols run them as a stack, and why the CJC-1295 DAC and Ipamorelin pages tend to get ordered together. The DAC version of CJC-1295 binds albumin and stretches its window to several days, which changes the timing math for the pairing.
Where it sits next to other options
Ipamorelin is not the only route to the same axis, and the alternatives make its niche clearer. Tesamorelin is a stabilized GHRH analog with real clinical data behind it, aimed at the GHRH side of the equation rather than the ghrelin side. IGF-1 LR3 skips the pituitary entirely and acts downstream, a different mechanism with a different risk conversation. And MK-677 (ibutamoren) hits the same GHS-R1a receptor as Ipamorelin but is an oral non-peptide with a long duration, so it produces a sustained IGF-1 rise instead of a short pulse. For the full map of the class, the growth hormone secretagogue overview is the pillar read.
Ipamorelin in research: where to find the dosing
In preclinical and early clinical work ipamorelin was given subcutaneously; the exact doses and schedule depended on the model and the aim. We do not present them here as instruction, the study data are collected in the reference Ipamorelin: dosing reference.
Purity, batch COA (Certificate of Analysis, a batch-specific lab certificate) and lot verification
For a peptide this short, identity and purity are the whole question. A pentapeptide is easy to name and hard to guarantee: the label means little without an analytical record behind it. Every Longeva batch ships with its own certificate of analysis, with HPLC (high-performance liquid chromatography, a purity-testing method) purity and mass-spec identity tied to the specific lot, not a generic spec sheet reused across production runs. You can read the record for the exact vial you hold on the Ipamorelin page, and the lot code on the box resolves to that COA through the verification page. That is the part price comparisons tend to skip, and the part that decides whether a research result means anything.
Bottom line
Ipamorelin earned its place by being selective rather than strong. It releases growth hormone as a clean pulse, leaves cortisol and prolactin mostly alone, and pairs predictably with a GHRH analog like CJC-1295. Whether that profile fits a given research question depends on the question. What should not be in question is what is actually in the vial, which is why the COA and the lot check come first.
